Interleukin-23 in perspective.
作者信息
Sherlock Jonathan P, Cua Daniel J
机构信息
Janssen Research & Development, Spring House, PA, USA.
Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
出版信息
Rheumatology (Oxford). 2021 Oct 19;60(Suppl 4):iv1-iv3. doi: 10.1093/rheumatology/keab461.
Abstract
摘要
相似文献
1
Interleukin-23 in perspective.白细胞介素-23的展望
Rheumatology (Oxford). 2021 Oct 19;60(Suppl 4):iv1-iv3. doi: 10.1093/rheumatology/keab461.
2
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.IL-23 的过去、现在和未来：推进 IL-23 科学和治疗的路线图。
Front Immunol. 2024 Apr 15;15:1331217. doi: 10.3389/fimmu.2024.1331217. eCollection 2024.
3
The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?IL-23/IL-17A 轴在脊柱关节炎中的作用：治疗学对发病机制的启示？
Curr Opin Rheumatol. 2020 Jul;32(4):349-356. doi: 10.1097/BOR.0000000000000719.
4
Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.银屑病关节炎中白细胞介素-12和白细胞介素-23的抑制作用
Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S115-8. Epub 2015 Oct 15.
5
Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.靶向 TNF-α/IL-23/IL-17 轴的生物制剂在银屑病和银屑病关节炎中的疗效差异。
Cytokine. 2018 Nov;111:182-188. doi: 10.1016/j.cyto.2018.08.025. Epub 2018 Aug 29.
6
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.IL-23 抑制剂治疗斑块状银屑病和银屑病关节炎：全面综述。
Am J Clin Dermatol. 2021 Mar;22(2):173-192. doi: 10.1007/s40257-020-00578-0.
7
Prospective new biologic therapies for psoriasis and psoriatic arthritis.用于银屑病和银屑病关节炎的前瞻性新型生物疗法。
J Drugs Dermatol. 2010 Aug;9(8):947-58.
8
Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.抑制白细胞介素-17、白细胞介素-23及TH17细胞通路在银屑病关节炎和银屑病治疗中的应用
Curr Opin Rheumatol. 2015 Mar;27(2):127-33. doi: 10.1097/BOR.0000000000000147.
9
Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.靶向治疗：它们让我们了解到的银屑病和银屑病关节炎的发病机制
Expert Rev Clin Immunol. 2017 Mar;13(3):207-222. doi: 10.1080/1744666X.2017.1241710. Epub 2016 Oct 17.
10
Guselkumab for the Treatment of Psoriasis.古塞奇尤单抗治疗银屑病。
BioDrugs. 2018 Apr;32(2):119-128. doi: 10.1007/s40259-018-0265-6.
引用本文的文献
1
Recent Advances in Gut Microbiota in Psoriatic Arthritis.银屑病关节炎中肠道微生物群的最新进展
Nutrients. 2025 Apr 11;17(8):1323. doi: 10.3390/nu17081323.
2
Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy.在银屑病患者中，古塞库单抗比阿达木单抗更能降低疾病及机制相关生物标志物：VOYAGE 1子研究
JID Innov. 2024 Jun 5;4(5):100287. doi: 10.1016/j.xjidi.2024.100287. eCollection 2024 Sep.
3
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.IL-23 的过去、现在和未来：推进 IL-23 科学和治疗的路线图。
Front Immunol. 2024 Apr 15;15:1331217. doi: 10.3389/fimmu.2024.1331217. eCollection 2024.
4
Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries.白细胞介素-23与纤维化自身免疫性疾病：新发现
J Clin Med. 2023 Sep 1;12(17):5699. doi: 10.3390/jcm12175699.
5
Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment.银屑病关节炎中的炎症细胞因子：发病机制的理解及其对治疗的影响。
Int J Mol Sci. 2023 Jul 19;24(14):11662. doi: 10.3390/ijms241411662.
6
Targeted Therapies in Psoriatic Arthritis-An Update.靶向治疗在银屑病关节炎中的应用进展。
Int J Mol Sci. 2023 Mar 28;24(7):6384. doi: 10.3390/ijms24076384.
7
The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis.IL-23 的作用及 IL-23 抑制剂在银屑病关节炎中的应用。
Musculoskeletal Care. 2022 Nov;20 Suppl 1(Suppl 1):S12-S21. doi: 10.1002/msc.1694. Epub 2022 Sep 7.
本文引用的文献
1
Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression.正常人类关节突关节中存在具有调节功能的常规 CD4+ 和 CD8+ T 细胞，并可诱导产生 IL-17A 和 TNF。
Ann Rheum Dis. 2020 Aug;79(8):1044-1054. doi: 10.1136/annrheumdis-2020-217309. Epub 2020 May 13.
2
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.在一项溃疡性结肠炎患者的随机 2 期研究中评估米利珠单抗的疗效和安全性。
Gastroenterology. 2020 Feb;158(3):537-549.e10. doi: 10.1053/j.gastro.2019.08.043. Epub 2019 Sep 4.
3
The Prevalence and Clinical Associations of Subclinical Sacroiliitis in Inflammatory Bowel Disease.炎症性肠病中无症状性骶髂关节炎的流行情况及其临床相关性。
Inflamm Bowel Dis. 2019 May 4;25(6):1066-1071. doi: 10.1093/ibd/izy339.
4
Diet Modifies Colonic Microbiota and CD4 T-Cell Repertoire to Induce Flares of Colitis in Mice With Myeloid-Cell Expression of Interleukin 23.饮食改变结肠微生物群和 CD4 T 细胞库，诱导白细胞介素 23 表达的髓系细胞的小鼠结肠炎发作。
Gastroenterology. 2018 Oct;155(4):1177-1191.e16. doi: 10.1053/j.gastro.2018.06.034. Epub 2018 Jun 15.
5
Ultrasonographic Enthesopathy and Disease Activity in Psoriatic Arthritis.银屑病关节炎的超声检查附着点病与疾病活动度
Open Access Maced J Med Sci. 2017 Aug 11;5(5):651-656. doi: 10.3889/oamjms.2017.070. eCollection 2017 Aug 15.
6
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.在中重度克罗恩病患者中使用选择性白细胞介素-23 抑制剂 risankizumab 进行诱导治疗：一项随机、双盲、安慰剂对照的 2 期研究。
Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12.
7
Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease.患有银屑病关节炎的患者肠道微生物多样性减少，其肠道微生物组与炎症性肠病中的失调类似。
Arthritis Rheumatol. 2015 Jan;67(1):128-39. doi: 10.1002/art.38892.
8
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.IL-23 通过作用于 ROR-γt+ CD3+CD4-CD8- 肌腱附着处固有 T 细胞诱导脊柱关节病。
Nat Med. 2012 Jul 1;18(7):1069-76. doi: 10.1038/nm.2817.
9
Structure and signalling in the IL-17 receptor family.白细胞介素-17受体家族的结构与信号传导
Nat Rev Immunol. 2009 Aug;9(8):556-67. doi: 10.1038/nri2586. Epub 2009 Jul 3.
10
Enthesis inflammation in recurrent acute anterior uveitis without spondylarthritis.无脊柱关节炎的复发性急性前葡萄膜炎中的附着点炎症
Arthritis Rheum. 2009 Jul;60(7):1985-90. doi: 10.1002/art.24636.
Zotero 插件